on February 23, 2026
Proprietary Blends vs Transparent Dosing: What Serious Athletes Need to Know
Proprietary blends are the single most consequential transparency problem in sports nutrition. A product can list creatine, citrulline, beta-alanine, and caffeine on its label — ingredients with robust peer-reviewed evidence at specific doses — and conceal that each is present at a fraction of the clinical threshold required to produce any measurable physiological effect. This is not a hypothetical risk. Research has documented that nearly half of all ingredients in commercially available pre-workout supplements are hidden within proprietary blends, making independent dose verification structurally impossible for the majority of products in the most commonly purchased supplement category. This article explains exactly what proprietary blends are, why they exist, what they conceal, and what supplement label transparency actually requires from brands that serious athletes should hold to an evidence-based standard.
TL;DR
- A proprietary blend lists multiple ingredients under a single total weight without disclosing individual amounts — making it structurally impossible to verify whether any ingredient is at a clinically relevant dose.
- The FDA permits proprietary blends under DSHEA 1994 on trade secret grounds. The intellectual property rationale does not hold for standard combinations of widely researched ingredients — the primary function is concealing underdosing from evidence-literate consumers.
- Research has found that nearly 44% of all ingredients in commercially available pre-workout supplements are hidden within proprietary blends.
- Performance supplements are dose-dependent: creatine at 500 mg, citrulline at 1 g, and beta-alanine at 800 mg are not functional doses regardless of how prominently they appear on the label.
- The only defense against proprietary blend underdosing is selecting products with full individual ingredient disclosure on the supplement facts panel.
- Transparent dosing means every active ingredient listed with its specific amount — enabling independent comparison against the clinical literature for each component.
- Fathom Nutrition does not use proprietary blends. Every ingredient in every product is individually disclosed, enabling the dose verification that evidence-based supplement selection requires.
What Is a Proprietary Blend?
Direct Answer
A proprietary blend is a grouping of two or more ingredients listed on a supplement facts panel under a collective name with a single total weight disclosed, but without the individual amounts of each component ingredient. The label tells the consumer that a set of ingredients is present in a combined amount — it does not tell them how much of each individual ingredient is in that total. For athletes who need to know whether specific compounds are present at clinically relevant doses, this structure provides insufficient information for any evidence-based evaluation.
The supplement facts panel is a regulated document. The FDA requires that every ingredient be listed and that the total weight of any proprietary blend be disclosed — but individual ingredient amounts within a blend are explicitly exempt from disclosure requirements when designated as proprietary. This creates a labeling structure that most athletes have encountered without understanding its implications: an entry that reads "Performance Matrix 7,000 mg (creatine monohydrate, beta-alanine, L-citrulline, taurine, L-tyrosine)" tells you the total weight of the blend and the ingredients in descending order of predominance by weight. It tells you nothing about whether creatine is present at 5 g or 500 mg, whether citrulline is present at 6 g or 600 mg, or whether any ingredient in that blend is at a dose the clinical literature associates with the claimed effect.
The Name Doesn't Matter — The Structure Does
Proprietary blends appear under a wide range of names: "Energy Complex," "Recovery Matrix," "Performance Formula," "Endurance Blend," "Anabolic Stack." The name varies; the information deficit is identical. Any label structure that lists multiple ingredients with a single combined weight rather than individual disclosures is a proprietary blend regardless of what it is called.
The Regulatory Context That Permits Them
Direct Answer
The Dietary Supplement Health and Education Act of 1994 (DSHEA) permits proprietary blend designations on the grounds that specific ingredient amounts may represent trade secrets warranting protection from competitor access. This regulatory permission was not designed to create a mechanism for concealing underdosing from consumers — but that is its primary functional consequence in the current supplement market.
DSHEA established that dietary supplements occupy a distinct regulatory category between foods and pharmaceutical drugs, requiring less pre-market oversight than drugs while still subject to FDA jurisdiction for safety and accurate labeling. Under DSHEA, manufacturers must list all ingredients but may designate specific ingredient amounts as proprietary when those amounts are claimed to constitute intellectual property. The regulation requires that the ingredient list appear in descending order of predominance even within a blend — giving consumers at least the qualitative ranking of ingredients by amount — but this ordering information is not a substitute for knowing actual amounts when evaluating whether a compound is at a functional dose.
The trade secret rationale has a theoretical foundation: if a manufacturer has invested substantially in developing a genuinely novel formulation with specific ratios that produce verified synergistic effects, there is a legitimate argument for protecting that specific formulation from competitors. In practice, this rationale is rarely applicable. Combinations of creatine monohydrate, caffeine, citrulline, beta-alanine, and taurine at literature-standard doses are not proprietary innovations — they are widely available ingredients at well-established doses that any competent formulator can independently arrive at through the same peer-reviewed literature available to any athlete who reads the evidence. The intellectual property protection argument provides a legally available mechanism that brands with underdosed formulations use to prevent consumers from discovering that underdosing.
Why Brands Use Proprietary Blends
Direct Answer
The primary commercial driver for proprietary blend use is cost management. Formulating multiple performance ingredients at their respective clinical dose thresholds is substantially more expensive than including them at token amounts. Proprietary blends allow brands to list premium ingredients — and appropriate the credibility of the research supporting those ingredients — while minimizing raw material cost by including each at a subclinical amount that the blend structure prevents consumers from detecting.
The economics create a structural pressure toward underdosing. Clinical doses of key performance ingredients are not cheap. Creatine monohydrate at 5 g, citrulline at 6–8 g, and beta-alanine at 3–4 g per daily serving represent meaningful raw material costs that compound across production volumes. A supplement brand formulating a pre-workout for sale at $35–$45 with 30 servings per container has approximately $0.80–$1.20 per serving in available cost of goods — a budget that cannot accommodate clinical doses of five or six evidence-supported ingredients simultaneously while maintaining the margins required for distribution, retail, and marketing overhead.
The Market Reality
The response to this economic pressure bifurcates. Brands that prioritize formulation integrity must either price at a premium, reduce their ingredient count to those they can fund at clinical doses, or absorb margin compression. Brands that prioritize margin use proprietary blends to include a comprehensive ingredient list at a fraction of the clinical dose cost — producing a label that reads as comprehensively formulated while delivering a product that functions as an underdosed collection of recognizable names. Proprietary blends exist precisely because this underdosing is not discoverable for consumers who cannot compare disclosed amounts against the clinical literature.
Performance Risks of Under-Dosing
Direct Answer
Under-dosing evidence-supported performance ingredients does not produce a proportionally smaller version of the clinical benefit — in most cases it produces no measurable benefit at all, because the physiological mechanisms underlying these ingredients' effects operate through threshold-dependent processes that require minimum effective doses to engage. An athlete consuming subclinical doses is receiving a supplement's marketing cost without its performance function.
Beta-alanine is among the clearest examples of threshold-dependent dosing. The performance mechanism — muscle carnosine elevation buffering hydrogen ion accumulation during high-intensity glycolytic exercise — requires sustained loading at 3.2–6.4 g/day for a minimum of 4–6 weeks to produce clinically significant carnosine increases. The ISSN Position Stand on beta-alanine is unambiguous: carnosine loading is proportional to cumulative beta-alanine intake over time, and amounts below the threshold daily dose produce proportionally smaller carnosine increases that may not reach the level required for detectable exercise performance improvements. A pre-workout including 800 mg of beta-alanine per serving produces the characteristic tingling (paresthesia) that convinces athletes the ingredient is active — without producing the sustained carnosine elevation that underlies its clinical evidence base.
Citrulline's dose-response relationship is similarly well-characterized. Research across multiple randomized controlled trials has established that 6–8 g of L-citrulline or 8 g of citrulline malate (2:1 ratio) in the pre-exercise period produce measurable increases in blood arginine concentration, nitric oxide synthesis markers, and in several studies, endurance performance and repetition counts in resistance training. A product delivering 2 g of citrulline — possible within a 7 g proprietary blend containing six other ingredients — does not produce the vascular effects its inclusion implies and does not represent evidence-based citrulline supplementation regardless of how prominently "L-Citrulline" appears in the marketing.
Research Finding — Pre-Workout Supplements
A study published in Nutrients examining 100 commercially available pre-workout supplements found that the majority of products included key ingredients at amounts below the doses used in the supporting research — a finding most severe for proprietary blend products, where the total blend weight made clinical dosing of multiple ingredients mathematically implausible.
| Ingredient | Evidence-Based Clinical Dose | Typical Amount in Proprietary Blend | Performance Consequence of Underdosing |
|---|---|---|---|
| Creatine monohydrate | 3–5 g/day maintenance | 500 mg–1.5 g (in blended products) | Insufficient phosphocreatine elevation; no measurable recovery, power, or volume benefit |
| L-Citrulline | 6–8 g pre-exercise | 1–3 g (in typical pre-workout blends) | Attenuated or absent nitric oxide response; no measurable endurance or pump benefit |
| Beta-alanine | 3.2–6.4 g/day (loading protocol) | 500 mg–1.5 g per serving | Paresthesia present; carnosine loading absent; no high-intensity fatigue resistance benefit |
| Caffeine | 3–6 mg/kg body weight | Often adequately dosed — cheap ingredient with direct sensory feedback on dose | When underdosed: reduced neural drive, attenuated perceived effort reduction |
| Betaine anhydrous | 2.5 g/day | 500 mg–1 g (in blended products) | No measurable power output or training volume benefit at sub-threshold doses |
| Sodium (electrolyte) | 300–1,000 mg/hr during prolonged exercise | Often 50–150 mg as a label token | Insufficient plasma volume maintenance; no meaningful sweat sodium replacement during sustained sessions |
The Compounding Cost of Systematic Underdosing
The performance risk of underdosing compounds over training months and years. An athlete who uses a proprietary-blend pre-workout for 12 months believing they are receiving clinical doses of citrulline, beta-alanine, and creatine has experienced a year of sessions without the vascular, carnosine-buffering, or phosphocreatine recovery benefits those ingredients were selected to provide — at the full cost of a premium-positioned product. The training adaptations that would have accumulated with genuinely functional supplementation cannot be recovered retroactively.
What Transparent Dosing Actually Means
Direct Answer
Transparent dosing means every active ingredient in a supplement product is listed on the supplement facts panel with its individual specific amount in milligrams or grams — enabling any athlete or practitioner to compare each ingredient against the clinical literature independently, without relying on the brand's claims about what the research supports. Transparency is the structural prerequisite for evidence-based supplement evaluation; it is not a bonus feature of premium products.
Full ingredient disclosure sounds like a baseline expectation. In practice it represents a meaningful differentiator in a market where nearly half of multi-ingredient pre-workout ingredients are concealed in blends. A fully transparent supplement label specifies not just what is present but how much — and where bioavailable forms are used, which form. "Magnesium bisglycinate 150 mg" provides more actionable information than "Magnesium 150 mg" even with individual amount disclosure, because the form determines the bioavailability of that disclosed amount. Complete transparency encompasses ingredient identity, form specificity, and individual amount — all three together provide the information set that evidence-based evaluation requires.
The transparency test: Can you compare every active ingredient in this product against its clinical dose range from a peer-reviewed source? If yes — the product is transparent. If any ingredient is grouped with others under a combined weight, or if only a generic compound name appears without a form specification — the product is not fully transparent, and independent quality evaluation is not possible.
Proprietary Blends vs Transparent Dosing: Direct Comparison
Direct Answer
The functional difference between a proprietary blend and a transparently dosed product is not in the ingredients listed or the total weight claimed — it is in whether an athlete can verify that what is claimed on the label corresponds to what the clinical literature requires for the claimed outcome. Transparency enables verification; a proprietary blend structurally prevents it.
| Feature | Proprietary Blend | Transparent Dosing |
|---|---|---|
| Individual ingredient amounts | Not disclosed; only total blend weight listed | Every ingredient listed with specific individual amount in mg or g |
| Clinical dose verification | Structurally impossible — amounts concealed | Possible for every ingredient — compare disclosed amount to peer-reviewed dose range |
| Stacking compatibility | Impossible — cannot calculate total daily intake of specific compounds across products | Possible — total daily intake across all products is calculable with full disclosure |
| Anti-doping risk management | Higher risk — undisclosed amounts may include compounds prohibited above certain thresholds | Lower risk — amounts known; can verify disclosed amounts are below prohibited thresholds |
| Brand accountability | Low — performance claims cannot be evaluated against formulation | High — disclosed amounts can be directly assessed against evidence supporting the claims |
| Consumer information parity | Asymmetric — brand knows what is in the product; consumer does not | Symmetric — consumer has the same formulation information the brand used to develop the product |
| Evidence of formulation confidence | Opacity suggests formulation would not withstand independent scrutiny | Disclosure signals confidence that the formulation holds up against the evidence it references |
| Practitioner assessment | Cannot be evaluated for athlete-specific appropriateness without lab analysis | Can be fully assessed by any qualified practitioner using the disclosed amounts |
| Label Structure Type | Example Label Entry | Information Provided | Clinical Dose Verifiable? |
|---|---|---|---|
| Full proprietary blend | Performance Complex 6,000 mg: Creatine monohydrate, L-citrulline, beta-alanine, taurine, N-acetyl-L-tyrosine, caffeine anhydrous | 6 ingredients present; total 6 g; descending order only | No — for any ingredient |
| Partial disclosure (hybrid) | Caffeine anhydrous 200 mg; Endurance Blend 4,000 mg: L-citrulline, beta-alanine, betaine anhydrous | Caffeine amount known; blend ingredients present at unknown amounts within 4 g total | Caffeine only — blend ingredients not verifiable |
| Full transparent disclosure | Creatine monohydrate 5,000 mg; L-citrulline 6,000 mg; Beta-alanine 3,200 mg; Caffeine (from green coffee) 200 mg; Sodium (as sodium citrate + sea salt) 350 mg; Potassium (as potassium citrate) 150 mg; Magnesium (as bisglycinate) 150 mg | Every ingredient with individual amount and specific form disclosed | Yes — for every ingredient; clinical comparison is immediate |
Fathom Nutrition — The Transparent Dosing Standard in Practice
Pre Workout
The "Full transparent disclosure" row in Table 3 above describes Fathom's Pre Workout label structure precisely — because that's what full transparency looks like in a multi-ingredient performance product. Every active ingredient is individually disclosed with its specific amount and form: natural caffeine from green coffee, citrulline, beta-alanine, taurine, N-Acetyl-L-Tyrosine, sodium (as sodium citrate + sea salt), potassium (as potassium citrate), and magnesium (as bisglycinate). No ingredient is grouped with any other under a combined weight. No proprietary blend designation. You can compare every component against the relevant clinical literature in under five minutes — which is the whole point. Informed Sport batch-certified.
Shop Pre Workout →How to Identify Proprietary Blends on Any Label
Direct Answer
Identifying proprietary blends requires looking for any structure where multiple ingredients are listed under a single total weight — regardless of what the blend is called. The blend name varies enormously; the structural indicator is consistent: a named grouping with a combined weight followed by ingredient names in parentheses or as a list, without individual amounts for each component.
Three-step label reading protocol for blend detection:
1. Locate the supplement facts panel and scan for any line entry that contains both a total weight and multiple ingredient names — this is always a blend structure.
2. Verify that every ingredient has its own individual weight entry separate from any blend total — if individual weights are absent for any active ingredient, those ingredients are concealed.
3. Evaluate whether the total blend weight could mathematically accommodate clinical doses of all listed ingredients simultaneously — a 5,000 mg blend listing six ingredients each with clinical doses in the 1–6 g range cannot contain all of them at functional amounts, making underdosing of at least some components mathematically certain regardless of what the marketing states.
1. Locate the supplement facts panel and scan for any line entry that contains both a total weight and multiple ingredient names — this is always a blend structure.
2. Verify that every ingredient has its own individual weight entry separate from any blend total — if individual weights are absent for any active ingredient, those ingredients are concealed.
3. Evaluate whether the total blend weight could mathematically accommodate clinical doses of all listed ingredients simultaneously — a 5,000 mg blend listing six ingredients each with clinical doses in the 1–6 g range cannot contain all of them at functional amounts, making underdosing of at least some components mathematically certain regardless of what the marketing states.
The evidence-based supplement selection framework covers the full label evaluation process — dose transparency, ingredient form assessment, and third-party certification verification — as an integrated evaluation system rather than isolated individual criteria.
How Fathom Nutrition Approaches Label Transparency
Direct Answer
Fathom Nutrition does not use proprietary blends. Every ingredient in every Fathom Nutrition product is listed on the supplement facts panel with its individual specific amount, enabling athletes to compare each ingredient against the clinical literature independently. This is not a marketing claim — it is a structural commitment verifiable directly on any Fathom Nutrition label without relying on the brand's assertions about its own quality.
The operational consequence of this transparency commitment is that Fathom Nutrition's formulation decisions are fully auditable by the athletes consuming the products. If any ingredient is at a dose an athlete considers suboptimal for their specific application, they can identify it immediately and make an informed decision about whether to supplement that ingredient additionally or seek a product with a higher dose. This auditable relationship between brand and athlete is only possible with full disclosure — and is the relationship that evidence-based athletes should expect as a baseline from any brand claiming to serve their performance needs.
Fathom Nutrition — No Proprietary Blends
Creatine Monohydrate
A single-ingredient product is the simplest possible transparency test: the label discloses one ingredient, one amount, one form. Fathom Creatine is 5 g of 200-mesh micronized creatine monohydrate per serving — the maintenance dose established in the ISSN Position Stand and across the broader creatine meta-analysis literature. No blend, no proprietary designation, no form ambiguity. NSF 455 certified for label accuracy with publicly available COA. If you've been using a creatine-containing proprietary blend where the total blend is 5 g and creatine shares that weight with five other ingredients, you are not getting 5 g of creatine.
Shop Creatine →
Fathom Nutrition — No Proprietary Blends
Hydrate+
Electrolyte products are among the most common targets for proprietary blend underdosing — particularly sodium, which is the most important electrolyte for sweat replacement during exercise but also the most expensive to include at meaningful amounts. Hydrate+ discloses every electrolyte amount individually: sodium (as sodium citrate + sea salt) 350 mg, potassium (as potassium citrate) 150 mg, magnesium (as bisglycinate) 150 mg. KSM-66 Ashwagandha and Tart Cherry Extract amounts are individually disclosed as well. You can verify every component against the relevant exercise hydration literature. NSF 455 certified, naturally flavored.
Shop Hydrate+ →FAQ
What is a proprietary blend in supplements?
A proprietary blend is a group of ingredients listed on a supplement facts panel under a single collective name with one total combined weight disclosed but without individual ingredient amounts. The FDA permits this labeling structure under DSHEA 1994. It means consumers know which ingredients are present but cannot determine how much of each individual ingredient the product contains. For athletes who need to verify that ingredients are present at clinically relevant doses, proprietary blends make that verification structurally impossible.
Are proprietary blends illegal?
No. Proprietary blends are explicitly permitted under U.S. federal supplement labeling regulations — specifically DSHEA 1994 — on the grounds of trade secret protection. The FDA requires that the total weight of a proprietary blend be disclosed and that ingredients be listed in descending order of predominance, but does not require individual ingredient amounts within a designated blend. Proprietary blends are legal; they are not consistent with the transparency standards that evidence-based supplement selection requires for serious athletes.
Why do supplement companies use proprietary blends?
The most common operational reason is cost management. Formulating multiple performance ingredients at their respective clinical dose thresholds requires substantially more raw material expenditure than including them at token amounts. Proprietary blends allow brands to list premium ingredients at subclinical doses without consumers being able to detect the underdosing from the label. The stated rationale — intellectual property protection — does not hold for standard combinations of widely researched ingredients at established doses, which represent no proprietary innovation requiring concealment from competitors.
How do I know if an ingredient in a supplement is at a clinical dose?
Only if the individual ingredient amount is disclosed on the label can you compare it against the clinical dose range from peer-reviewed research. Search the ISSN Position Stands for the ingredient — freely accessible through the Journal of the International Society of Sports Nutrition — for the clinical dose references most relevant to performance supplementation. For ingredients not covered by ISSN standards, search PubMed for systematic reviews or meta-analyses in trained human populations and identify the dose range used in trials demonstrating the claimed outcomes. If the disclosed amount falls below that range, the ingredient is underdosed regardless of how prominently it appears on the label.
What is the performance risk of using underdosed supplements?
Most performance supplements operate through threshold-dependent mechanisms that require minimum effective doses to engage. Beta-alanine below 3–4 g/day produces paresthesia but not clinically meaningful carnosine loading. Citrulline below 6 g does not produce measurable nitric oxide and hemodynamic effects. Creatine below 3 g/day does not reliably elevate phosphocreatine to the level the performance literature establishes. An athlete consuming subclinical doses is receiving the marketing cost of the supplement without its performance function — and accumulating that deficit across every session and training week the underdosed protocol continues.
Is transparent dosing a reliable indicator of overall supplement quality?
Transparent dosing is a necessary but not sufficient indicator of quality. A supplement can disclose every ingredient amount individually while still being underdosed — disclosure enables detection of underdosing but does not guarantee clinical dosing. What full label transparency guarantees is that the athlete has the information required to identify underdosing and make an informed decision. A product without individual amount disclosure guarantees only that underdosing cannot be detected from the label alone. Transparency is the prerequisite for quality evaluation, not the quality assurance itself.
Can a proprietary blend supplement be effective?
Theoretical vs Practical
Theoretically yes — a brand could formulate a genuinely clinical-dose product and choose a proprietary blend designation to conceal its specific ratios from competitors. In practice, the economics of supplement formulation make this scenario uncommon for multi-ingredient products at standard retail price points: clinical dosing of multiple performance ingredients simultaneously requires raw material costs that most commodity supplement pricing cannot accommodate. The absence of individual amount disclosure prevents consumers from verifying the claim either way. For athletes whose selection decisions are based on evidence, a proprietary blend product provides insufficient information for a confident purchase decision regardless of the brand's stated intentions.
What should I look for on a supplement label to avoid proprietary blends?
Scan the supplement facts panel for any entry that contains multiple ingredient names under a single combined weight — this structure, regardless of what it is called, is a proprietary blend. Verify that every active ingredient has its own individual weight entry in milligrams or grams, separate from any combined total. Check that ingredient forms are specified rather than listed by generic compound name. And look for named third-party certification from programs like NSF Certified for Sport or Informed Sport, which require label accuracy verification as a certification prerequisite — adding independent quality assurance that disclosed amounts correspond to what is actually in the product. The full framework for this evaluation is covered in the third-party testing guide.
References
- U.S. Food and Drug Administration. (2024). Dietary Supplements: Labeling Requirements and Regulatory Framework under DSHEA. fda.gov/food/dietary-supplements
- Kreider, R. B., et al. (2017). International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition, 14(1), 18. Link
- Trexler, E. T., et al. (2015). International Society of Sports Nutrition position stand: Beta-Alanine. Journal of the International Society of Sports Nutrition, 12(1), 30. Link
- Guest, N. S., et al. (2021). International Society of Sports Nutrition position stand: caffeine and exercise performance. Journal of the International Society of Sports Nutrition, 18(1), 1. Link
- Jagim, A. R., Camic, C. L., & Harty, P. S. (2019). Common ingredient profiles of multi-ingredient pre-workout supplements. Nutrients, 11(2), 254. Link
- Kerksick, C. M., et al. (2018). ISSN exercise & sports nutrition review update: research & recommendations. Journal of the International Society of Sports Nutrition, 15(1), 38. Link
